NASDAQHealth CareMedical Instruments & SuppliesSnapshot 2026-07-23
Reading FEMY? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a speculative growth bet. FEMY is navigating a volatile management landscape while trying to capitalize on growth in the healthcare sector, particularly in fertility and birth control products.
The market currently prices FEMY at a premium compared to its peers, indicating high expectations despite its recent weak financial performance. This suggests that investors may be anticipating a turnaround that has not yet materialized.
FEMY's fundamentals show mixed results, with revenue growth from product sales but ongoing losses. Management has made progress in reducing losses and advancing product commercialization, but the overall financial performance remains weak.
The thesis hinges on the performance of sector bellwethers like ISRG, MDLN, and BDX. If these companies continue to perform well, it could provide a favorable backdrop for FEMY. Conversely, any negative guidance from these peers could significantly impact FEMY's outlook.
Over the next 1 to 3 years, FEMY's prospects depend on sector momentum and management execution amidst a challenging financial landscape. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. Femasys regained Nasdaq listing compliance. This supports its growth strategy and operational focus. There are no new threats to the thesis at this time.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Earnings results will show if the company continues to improve operating income. This is key for future funding.
Confirms:Operating income improves to less than -$4M for Q2 2026.
Disproves:Operating income worsens or remains above -$4.5M for Q2 2026.
Why it matters: Having cash is important for running the business and supporting growth.
Confirms:Cash and cash equivalents will be over $5 million in the next update.
Disproves:Cash and cash equivalents drop below $4 million before Q3 2026.
Why it matters: The reverse stock split aims to adjust the capital structure. A positive market reaction could indicate investor confidence.
Confirms one read:Share price stabilizes or increases after the reverse stock split.
Confirms the other:The share price drops a lot after the reverse stock split.
Why it matters: This report will show if the company continues to improve its financial performance. Investors will look for signs of progress in revenue and operating income.
Confirms:Earnings report shows revenue growth of more than 10% compared to the previous quarter.
Disproves:Earnings report shows revenue decline or no growth compared to the previous quarter.
Why it matters: The new COO could bring fresh strategies to improve operations. This may affect overall performance.
Confirms one read:The new COO announced positive changes to operations in three months.
Confirms the other:No big improvements in operations were reported in three months.
Why it matters: Having enough cash is important for running the business. Updates will show financial health.
Confirms:Cash reserves reported above $5M in Q2 earnings.
Disproves:Cash reserves reported below $3M in Q2 earnings.
Why it matters: The company needs enough cash to fund operations after the stock split. A strong cash position is crucial for stability.
Confirms:A press release shows cash reserves went up after the split. They are over $5 million.
Disproves:Cash reserves fall below $3 million after the reverse stock split.
Why it matters: Enrollment progress is key for the FemBloc product's path to U.S. FDA approval.
Confirms:They will announce when at least 100 patients join the FINALE trial.
Disproves:Enrollment stalls or fails to reach 100 participants by the next earnings call.
Why it matters: New partnerships can help Femasys reach more customers and increase sales.
Confirms:They will announce at least one new partnership to improve market access.
Disproves:No new partnerships announced by the next earnings call or existing partnerships show no progress.
